Medical Condition News

RSS

New insights into accelerated aging in young sickle cell patients

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 21 on November 14, 2024, entitled, "Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression."

11 Dec 2024

Exosomes: A double-edged sword in hepatocellular carcinoma

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance.

11 Dec 2024

Blood pressure fluctuations linked to problems with thinking and memory skills

Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking and memory skills, according to a study published in the December 11, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology.

11 Dec 2024

Novel treatment for inflammatory skin conditions could be on the horizon

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study published today in Science Translational Medicine.

11 Dec 2024

Next-generation cell-penetrating antibodies could transform cancer treatment

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

11 Dec 2024

Study highlights global surge in early-onset colorectal cancer

A new study led by American Cancer Society (ACS) researchers shows that early-onset colorectal cancer (CRC) incidence rates are rising in 27 of 50 countries/territories worldwide, 20 of which have either exclusive or faster increases for early-onset disease.

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024